RNAZ
Transcode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.70
+0.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.75
From 52W high−88.84%
Volume29260.00
Market cap$28.78M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.75
From 52W high
−88.84%
Volume
29260.00
Market cap
$28.78M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.4x
P/E (TTM)
—
RSI (14)
45.5
MomentumView details →
1D Return
+0.00%
YTD Return
−73.94%
SummaryUpdated Jun 1, 2026
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Boston, Massachusetts. The company went public in July 2021 and focuses on developing innovative RNA-based therapeutics and diagnostics specifically targeting metastatic cancer. TransCode operates in the highly specialized field of precision oncology, utilizing advanced RNA interference (RNAi) and gene editing technologies to address one of cancer's most challenging aspects - metastasis, which occurs when cancer cells spread from their original location to other parts of the body.
Similar companies
Latest newsMore news →
Transcode Therapeutics, Inc. announced that a poster on its TTX-MC138 Phase 1a clinical evaluation was accepted for presentation at the Transcode Therapeutics, Inc. in Madrid on October 23, 2026.14h agoNatera, Inc. and Transcode Therapeutics, Inc. announced a collaboration to support enrollment in TransCode’s Phase 2a trial of TTX-MC138 in patients with colorectal cancer.7d agoTransCode Therapeutics reported updated Phase 1a clinical trial follow-up data for TTX-MC138 in heavily pretreated patients with advanced solid tumors, showing a 71.4% stable disease rate among 14 efficacy-evaluable patients and no dose-limiting toxicities.22d ago